Isabelle Kindts1, Karin Stellamans2, Ignace Billiet3, Hans Pottel4, Antoon Lambrecht2. 1. Department of Radiation Oncology, AZ Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium. Isabellekindts@hotmail.com. 2. Department of Radiation Oncology, AZ Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium. 3. Department of Urology, AZ Groeninge Hospital, Kortrijk, Belgium. 4. Biostatistics, Faculty of Medicine, Catholic University Leuven Kulak, Kortrijk, Belgium.
Abstract
PURPOSE: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) 125I brachytherapy (BT) for localized prostate cancer. PATIENTS AND METHODS: A total of 192 patients (≤65-years-old) were treated with LDR 125I-BT ± hormone therapy. Local failure was defined as any prostate-specific antigen (PSA) rise leading to salvage treatment or biochemical failure according to the Phoenix definition. A bounce was defined as a rise in the nadir of ≥0.2 ng/mL followed by spontaneous return. Proportions were compared using Fisher's exact tests; continuous variables using the unpaired t-test or its non-parametric equivalent. Cox proportional hazards models were applied for multivariable survival analysis. RESULTS: Median follow-up was 66 months. The 5‑year local recurrence-free survival was 96.1%. Biopsy-proven local recurrence developed in 13 patients, 4 had a Phoenix-defined recurrence at the last follow-up. Androgen deprivation therapy was started in 1 patient without proven recurrence. Univariable risk factors for local recurrence were: at least 50% positive biopsies, intermediate risk, treatment with neoadjuvant hormone therapy, low preimplantation volume receiving 100% of the prescribed dose, and no bounce development. Hormone-naïve patients not attaining a PSA value <0.5 ng/mL during follow-up also had a higher risk of local recurrences. Cox regression demonstrated that the variables "at least 50% positive biopsies" and "bounce" significantly impacted local failure (hazard ratio, HR 1.02 and 11.59, respectively). A bounce developed in 70 patients (36%). Younger patients and those treated with a lower activity per volume had a higher chance of developing a bounce in the Cox model (HR 0.99 and 0.04, respectively). CONCLUSION: For younger men, LDR BT is a valid primary curative treatment option in low-risk and is to consider in intermediate-risk localized prostate cancer.
PURPOSE: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) 125I brachytherapy (BT) for localized prostate cancer. PATIENTS AND METHODS: A total of 192 patients (≤65-years-old) were treated with LDR 125I-BT ± hormone therapy. Local failure was defined as any prostate-specific antigen (PSA) rise leading to salvage treatment or biochemical failure according to the Phoenix definition. A bounce was defined as a rise in the nadir of ≥0.2 ng/mL followed by spontaneous return. Proportions were compared using Fisher's exact tests; continuous variables using the unpaired t-test or its non-parametric equivalent. Cox proportional hazards models were applied for multivariable survival analysis. RESULTS: Median follow-up was 66 months. The 5‑year local recurrence-free survival was 96.1%. Biopsy-proven local recurrence developed in 13 patients, 4 had a Phoenix-defined recurrence at the last follow-up. Androgen deprivation therapy was started in 1 patient without proven recurrence. Univariable risk factors for local recurrence were: at least 50% positive biopsies, intermediate risk, treatment with neoadjuvant hormone therapy, low preimplantation volume receiving 100% of the prescribed dose, and no bounce development. Hormone-naïve patients not attaining a PSA value <0.5 ng/mL during follow-up also had a higher risk of local recurrences. Cox regression demonstrated that the variables "at least 50% positive biopsies" and "bounce" significantly impacted local failure (hazard ratio, HR 1.02 and 11.59, respectively). A bounce developed in 70 patients (36%). Younger patients and those treated with a lower activity per volume had a higher chance of developing a bounce in the Cox model (HR 0.99 and 0.04, respectively). CONCLUSION: For younger men, LDR BT is a valid primary curative treatment option in low-risk and is to consider in intermediate-risk localized prostate cancer.
Authors: Christopher Herbert; W James Morris; Mira Keyes; Jeremy Hamm; Vincent Lapointe; Michael McKenzie; Thomas Pickles; Ingrid Spadinger Journal: Radiother Oncol Date: 2012-02-10 Impact factor: 6.280
Authors: Daniel S Engeler; Christoph Schwab; Armin F Thöni; Werner Hochreiter; Ladislav Prikler; Stefan Suter; Patrick Stucki; Johann Schiefer; Ludwig Plasswilm; Hans-Peter Schmid; Paul Martin Putora Journal: Strahlenther Onkol Date: 2015-06-23 Impact factor: 3.621
Authors: Edan Y Shapiro; Soroush Rais-Bahrami; Carol Morgenstern; Barbara Napolitano; Lee Richstone; Louis Potters Journal: J Urol Date: 2009-02-23 Impact factor: 7.450
Authors: Robert F Wolff; Steve Ryder; Alberto Bossi; Alberto Briganti; Juanita Crook; Ann Henry; Jeffrey Karnes; Louis Potters; Theo de Reijke; Nelson Stone; Marion Burckhardt; Steven Duffy; Gillian Worthy; Jos Kleijnen Journal: Eur J Cancer Date: 2015-08-05 Impact factor: 9.162
Authors: Frank A Critz; W Hamilton Williams; A Keith Levinson; James B Benton; Frederick J Schnell; Clinton T Holladay; Philip D Shrake Journal: J Urol Date: 2003-11 Impact factor: 7.450